Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Modulation of the vasopressin system for the treatment of CNS diseases.

Ryckmans T.

Curr Opin Drug Discov Devel. 2010 Sep;13(5):538-47. Review.

PMID:
20812145
2.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.

Prog Brain Res. 2002;139:197-210. Review.

PMID:
12436936
3.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.

Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Review.

PMID:
18655903
4.

Vasopressin V1a and V1b receptors: from molecules to physiological systems.

Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A.

Physiol Rev. 2012 Oct;92(4):1813-64. doi: 10.1152/physrev.00035.2011. Review.

PMID:
23073632
5.

Vasopressin antagonists as anxiolytics and antidepressants: recent developments.

Simon NG, Guillon C, Fabio K, Heindel ND, Lu SF, Miller M, Ferris CF, Brownstein MJ, Garripa C, Koppel GA.

Recent Pat CNS Drug Discov. 2008 Jun;3(2):77-93. Review.

PMID:
18537767
6.
7.

Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.

Chan WY, Wo NC, Stoev ST, Cheng LL, Manning M.

Exp Physiol. 2000 Mar;85 Spec No:7S-18S. Review.

PMID:
10795902
8.

Recent progress in the discovery and development of negative allosteric modulators of mGluR5.

Lindsley CW, Emmitte KA.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):446-57. Review.

PMID:
19562641
9.

Molecular pharmacology and modeling of vasopressin receptors.

Thibonnier M, Coles P, Thibonnier A, Shoham M.

Prog Brain Res. 2002;139:179-96. Review.

PMID:
12436935
10.

Central nervous system effects of the neurohypophyseal hormones and related peptides.

de Wied D, Diamant M, Fodor M.

Front Neuroendocrinol. 1993 Oct;14(4):251-302. Review.

PMID:
8258377
11.

New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions.

Egashira N, Mishima K, Iwasaki K, Oishi R, Fujiwara M.

J Pharmacol Sci. 2009 Jan;109(1):44-9. Review.

13.

Vasopressin receptor antagonists: potential indications and clinical results.

Arai Y, Fujimori A, Sudoh K, Sasamata M.

Curr Opin Pharmacol. 2007 Apr;7(2):124-9. Epub 2007 Feb 9. Review.

PMID:
17292670
14.

An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.

Serradeil-Le Gal C, Wagnon J 3rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A.

CNS Drug Rev. 2005 Spring;11(1):53-68. Review.

16.

Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].

Ali F, Raufi MA, Washington B, Ghali JK.

Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. Review. Erratum in: Cardiovasc Drug Rev. 2007 Winter;25(4):397.

PMID:
17919259
17.

Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.

Serradeil-Le Gal C, Derick S, Brossard G, Manning M, Simiand J, Gaillard R, Griebel G, Guillon G.

Stress. 2003 Sep;6(3):199-206. Review.

PMID:
13129813
18.

Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene.

Mayinger B, Hensen J.

Exp Clin Endocrinol Diabetes. 1999;107(3):157-65. Review.

PMID:
10376439
19.

Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure.

Goldsmith SR.

Cleve Clin J Med. 2006 Jun;73 Suppl 2:S20-3; discussion S30-3. Review.

PMID:
16786909
20.

Central vasopressin and oxytocin release: regulation of complex social behaviours.

Veenema AH, Neumann ID.

Prog Brain Res. 2008;170:261-76. doi: 10.1016/S0079-6123(08)00422-6. Review.

PMID:
18655888

Supplemental Content

Support Center